Status:
COMPLETED
Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation
Lead Sponsor:
AstraZeneca
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The current study is designed to assess the efficacy and safety of iv AZD7009 in conversion from AF
Eligibility Criteria
Inclusion
- Clinical indication for cardioversion of Atrial Fibrillation. Effective oral anticoagulation according to local routines or a TEE without any finding of intracardial thrombus or signs of thrombogenecity
Exclusion
- Clinically significant sinus and/or AV node dysfunction. Serum or plasma potassium \<3.8 mmol/L or \>5.0 mmol/L. QTc(Bazett) \>450 ms. Any QRS duration \>150 ms
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2006
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00255281
Start Date
September 1 2005
End Date
May 1 2006
Last Update
December 6 2007
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Esbjerg, Denmark
2
Research Site
Hellerup, Denmark
3
Research Site
Hvidovre, Denmark
4
Research Site
Svendborg, Denmark